We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 115

News Bytes - August 29, 2013

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 29 2013

The U.S. Patent and Trademark Office (USPTO) slates its next Software Partnership meeting for October 17, 2013, at the U.C. Berkeley School of Law in

Stakeholders provide input on FDA review standards for biosimilars

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 18 2010

The Food and Drug Administration (FDA) recently conducted a two-day hearing to begin the process of determining how it will go about creating review standards for the generic copies (biosimilars) of prescription drugs developed from biological materials (biologics

Pharma merger activity attributed to “patent cliff”

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 18 2010

Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies

Medical treatment claims deemed patentable on reconsideration after Bilski

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 13 2011

The Federal Circuit Court of Appeals has confirmed its earlier decision, rendered before Bilski v. Kappos, 130 S. Ct. 3218 (2010), was decided, and ruled that methods for determining the optimal dosage of thiopurine drugs used to treat gastrointestinal and non-gastrointestinal autoimmune diseases recite patentable subject matter under 101

Federal Circuit reverses Patent Appeals Board on obviousness ruling and commercial success evidence

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 13 2011

The Federal Circuit Court of Appeals has determined that the Board of Patent Appeals and Interferences incorrectly rejected on obviousness grounds a patent claim involving physical and air shields to prevent the clogging of a nozzle to a Wurster coater, which sprays coating material onto pharmaceutical ingredients

Biotech trade group seeks USDA involvement in gene patents lawsuit

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 21 2010

The Biotechnology Industry Organization (BIO) has asked U.S. Department of Agriculture (USDA) Secretary Tom Vilsack to urge the Department of Justice, which is considering the federal government's position in litigation about patent protection for isolated DNA sequences, to "strongly defend the patentability of such basic biotech inventions."

U.S. Supreme Court to decide whether Stanford owns patents for invention funded with federal dollars

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 4 2010

The U.S. Supreme Court has granted the appeal of a Federal Circuit decision that rejected on standing grounds a university’s claim to patents that arose out of an NIH-financed research project involving technology for detecting HIV levels in a patient’s blood

U.S. government takes position on patentability of isolated genomic DNA

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 4 2010

The U.S. Department of Justice has filed an amicus brief in a lawsuit pending before the Federal Circuit Court of Appeals to address the question of whether and to what extent genetic discoveries may be patented

News bytes

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • February 7 2011

The U.S. Patent & Trademark Office announces an agreement with the European Patent Office on a joint patent classification system that “will use the European Classification System as a basis and incorporate the best classifications practices of the USPTO.”

Administration budget-cut plan includes reducing data exclusivity for biologic drugs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • February 24 2011

Among other provisions included in President Barack Obama’s (D) $3.7 trillion budget proposal is a plan to give biotech drugs seven years of market exclusivity rather than the 12 years already in effect